Search for: "Jennings v. State" Results 521 - 540 of 585
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Jul 2018, 4:39 am by Edith Roberts
At the Penn Journal on Regulation’s Regulatory Review, Sarah Paoletti maintains that “[d]ue to th[is term’s] ruling [in Jennings v. [read post]
6 May 2011, 3:46 pm by Jon L. Gelman
” Although the Sherman Anti-trust Act had been passed in 1890, the United States Supreme Court decision of U.S. v. [read post]
24 Jun 2014, 1:00 pm by Jeff Hermes
The launch of the OMLN marked a quantum leap in the breadth and impact of the CMLP's services, placing individual online media clients in contact with skilled media and business attorneys throughout the United States willing to provide legal services on a pro bono or reduced fee basis. [read post]
24 Jun 2014, 12:00 am by Jeff Hermes
The launch of the OMLN marked a quantum leap in the breadth and impact of the CMLP's services, placing individual online media clients in contact with skilled media and business attorneys throughout the United States willing to provide legal services on a pro bono or reduced fee basis. [read post]
30 Mar 2013, 3:50 am
Solum and Tun-Jen Chiang embarked on a mission to provide a new, original approach to the matter, which is presented in 'The Interpretation-Construction Distinction in Patent Law', a 73-page long article for the Yale Law Journal. [read post]
28 Aug 2024, 3:00 am by jonathanturley
When the censorship system was recently put before the Supreme Court in Murthy v. [read post]
11 Mar 2016, 7:55 am by Rebecca Tushnet
TushnetSpeakers and Papers/Commentators:Tun-Jen Chiang, “The Paradox of IP”: A paper looking for a theory. [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO: (Managing… [read post]
18 Nov 2011, 11:26 am by Rebecca Tushnet
Might work better if claims were confined to copyright v. patent w/r/t software? [read post]